VEGFA and dementia: nAMD patients with dementia were also seen less often by eye care providers (1.33 vs. 2.07 visits, RR 0.74, 95% CI: 0.70–0.79, p < 0.0001) and received fewer intravitreal anti-VEGF injections (0.64 vs. 1.19 injections; RR 0.64, 95% CI: 0.58–0.69, p < 0.0001) than nAMD patients without dementia.